15 November 2017 - - Raritan, New Jersey-based healthcare solutions developer Janssen Research and Development, LLC has released a new analysis from the CANVAS Program, which showed Invokana (canagliflozin) demonstrated a reduced risk of cardiovascular (CV) outcomes in patients with and without a history of CV disease, the company said.
Invokana also achieved similar and proportional risk reductions for hospitalization due to heart failure and renal outcomes in each of the primary and secondary prevention groups.
This analysis of CANVAS examined two high-CV-risk type 2 diabetes patient groups: those with a history of CV disease (secondary prevention) and those with only risk factors for CV disease (primary prevention).
Both patient groups showed CV outcomes consistent with the overall reduction seen in CV events: primary (HR: 0.98; 95% CI: 0.74 to 1.30) and secondary (HR: 0.82; 95% CI: 0.72 to 0.95), with no statistical evidence of between-group heterogeneity (p = 0.18).
Comparable effects were also observed for other CV and renal outcomes across the primary and secondary prevention groups.
No new adverse events were observed during this additional analysis than what was previously reported from the CANVAS Program.
Invokana is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Janssen, a pharmaceutical company of Johnson and Johnson (NYSE: JNJ), works to find new and better ways to prevent, intercept, treat, and cure disease.